⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IONS News
Ionis Pharmaceuticals, Inc. Common Stock
Ionis reports first quarter 2026 financial results and highlights progress on key programs
businesswire.com
IONS
Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B
businesswire.com
IONS
Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsight
globenewswire.com
TSEM
TAK
MRK
IONS
SLN
INCY
JNJ
VNDA
Form 8-K
sec.gov
IONS
Liberty All-Star ® Growth Fund, Inc. March 2026 Monthly Update
businesswire.com
NVDA
AAPL
MSFT
GOOGL
AMZN
CW
OLLI
MPWR
TPR
LLY
CASY
LNG
DB
IONS
IPGP
MU
TER
ABBV
COMP
DHR
PSTG
VRTX
Oligonucleotides Market Research and Competitive Landscape Report 2026 Featuring Novartis, Astellas, Alnylam Pharmaceuticals, Ionis Pharmaceuticals
globenewswire.com
NVS
ALNY
IONS
FDA Approves High Dose Regimen of SPINRAZA® for Spinal Muscular Atrophy, Reflecting Progress Made Possible Through Decades of MDA Supported Research
globenewswire.com
BIIB
IONS
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
globenewswire.com
IONS
BIIB
EMA validates indication extension application for Tryngolza® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)
prnewswire.com
IONS
Kardigan Announces Positive Phase 2 Data for Tonlamarsen in Patients with Uncontrolled Hypertension Presented as Late-Breaker at ACC.26 and Simultaneously Published in JACC
businesswire.com
IONS
BMY
SNY